Delaware/Christiana Care CCOP was originally funded by the NCI in 1987 and has continued to be an exemplary participant since that time. Currently, CALGB, NSABP, ECOG, RTOG, GOG, COG, Wake Forest, URCC and CTSU are utilized as research bases. ACOS-OG trials have also been accessed although not through the CCOP mechanism. Our extensive catchment area includes all of Delaware and portions of New Jersey, northeastern Maryland and southeastern Pennsylvania (Delaware and Chester counties). Delaware ranks 3rd in the nation for all cancer site disease incidence, Maryland ranks 35th, New Jersey 5th and Pennsylvania 6th (2007 USCS Data). Our research base represents a population base in excess of 2 million people with extensive protocol entry potential. Under the leadership of Stephen S.Grubbs, M.D., Principal Investigator and Kandie Dempsey, MS, RN, OCN, Director, CCOP investigators, project coordinators and data managers will continue to participate in cooperative group core committees and leadership positions. Our mission is to continue accruals to both treatment and cancer control studies. In addition, CCHS is committed to having personnel continue to provide significant contributions in leadership roles on cooperative group core committees and as cooperative group protocol study chairs. The overall impact of this grant will be to ensure continuation and stimulate expansion of CCOP activities, including treatment and cancer control research, at Christiana Care Health Services and its affiliates throughout the catchment area.

Public Health Relevance

Our mission statement is to provide the community with coordinated access to cancer related clinical trials in order to reduce cancer incidence, morbidity and mortality while improving quality of life. Participation in the CCOP provides us with the opportunity to work towards our mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA045418-27S1
Application #
8850965
Study Section
Special Emphasis Panel (ZCA1-SRLB-E (J1))
Program Officer
St Germain, Diane
Project Start
1987-08-05
Project End
2014-07-31
Budget Start
2013-06-01
Budget End
2014-07-31
Support Year
27
Fiscal Year
2014
Total Cost
$237,321
Indirect Cost
$85,581
Name
Christiana Care Health Services, Inc.
Department
Type
DUNS #
077069243
City
Newark
State
DE
Country
United States
Zip Code
19713
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Shulman, Lawrence N; Berry, Donald A; Cirrincione, Constance T et al. (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-7
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Burstein, Harold J; Cirrincione, Constance T; Barry, William T et al. (2014) Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women J Clin Oncol 32:3959-66

Showing the most recent 10 out of 95 publications